NYSE · ANVS
Healthcare · Biotechnology
$1.04
Down-$0.08 (-7.14%)
Updated Sep 17, 2026, 3:29 AM
SID Score
2.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
ANVS does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning ANVS.
ANVS research
Company profile and research snapshot.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 28, 2026 | Roth Capital | Buy | — |
| Aug 18, 2026 | Canaccord Genuity | Buy | — |
| Jul 8, 2026 | Roth Capital | Buy | — |
| Apr 14, 2026 | Canaccord Genuity | Buy | — |
| Sep 30, 2025 | Canaccord Genuity | Buy | — |
No generated briefing is available yet.
Finnhub · Apr 13, 2026
MALVERN, Pa. - Annovis Bio, Inc. , a Phase 3 clinical - stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease...
Benzinga · Apr 10, 2026
Financing secures path to first NDA submission for buntanetap6-Month symptomatic data readout anticipated Q1 2027Alzheimer's disease Phase 3 trial 75% enrolledParkinson's disease open-label study 28% enrolledMALVERN,
Fintel · Apr 9, 2026
Benzinga · Apr 9, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ANVS.
